This included med/legal/regulatory reviews at Amgen, Eli Lilly, Pfizer, Endo Pharmaceuticals, Celphalon, and Bristol-Myers Squibb.
- Enbrel (entanocept; Amgen): RA, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis
- Erbitux (cetuximab; Eli Lilly): mAb for metastatic CRC and certain head and neck cancers
- Inlyta (axitinib; Pfizer): advanced renal cell carcinoma
- Nplate (romiplostim; Amgen): chronic immune thrombocytopenia (ITP)
- Prolia (denosumab; Amgen): osteoporosis
- Sumavel (sumatriptan injection; Endo Pharmaceuticals): acute migraine with or without cluster and acute treatment of cluster headache
- Xeljanz (tofacitinib; Pfizer): rheumatoid arthritis
- Treanda (bendamustine; Celphalon): CLL and NHL
- Yervoy (ipilimumab; Bristol-Myers Squibb): melanoma